An Open-label Extension of BPS-314d-MR-PAH-302 in Pulmonary Arterial Hypertension Patients
Phase of Trial: Phase III
Latest Information Update: 07 Nov 2019
Price : $35 *
At a glance
- Drugs Esuberaprost (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Acronyms BEAT OLE
- Sponsors Lung Biotechnology
- 31 Oct 2019 Status changed from active, no longer recruiting to completed.
- 06 Aug 2019 Planned End Date changed from 1 Jun 2019 to 31 Aug 2019.
- 06 Aug 2019 Planned primary completion date changed from 1 Jun 2019 to 31 Aug 2019.